SKYRIZI — Net revenues
Products & Services · Net revenuesAbbVie SKYRIZI — Net revenues increased by 6.3% to $5.01B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 32.5%, from $3.78B to $5.01B. Over 4 years (FY 2021 to FY 2025), SKYRIZI — Net revenues shows an upward trend with a 56.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong market penetration, successful clinical adoption, and effective commercial execution, while a decrease may signal increased competition, patent expiration, or loss of market share.
Detailed definition
This metric represents the total gross sales of the specific pharmaceutical product line after accounting for returns, a...
Peer comparison
Comparable to net revenue reporting for key blockbuster drugs or flagship therapeutic franchises at other large-cap pharmaceutical companies.
abbv_segment_skyrizi_net_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $674.00M | $796.00M | $895.00M | $940.00M | $1.25B | $1.40B | $1.58B | $1.36B | $1.88B | $2.13B | $2.39B | $2.01B | $2.73B | $3.21B | $3.78B | $3.43B | $4.42B | $4.71B | $5.01B |
| QoQ Change | — | +18.1% | +12.4% | +5.0% | +33.2% | +11.6% | +12.8% | -13.7% | +38.5% | +12.9% | +12.6% | -16.1% | +35.8% | +17.5% | +17.9% | -9.3% | +29.1% | +6.4% | +6.3% |
| YoY Change | — | — | — | — | +85.8% | +75.5% | +76.1% | +44.7% | +50.4% | +52.2% | +51.9% | +47.6% | +44.8% | +50.8% | +57.8% | +70.6% | +62.2% | +46.9% | +32.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is AbbVie's skyrizi — net revenues?
- AbbVie (ABBV) reported skyrizi — net revenues of $5.01B in Q4 2025.
- How has AbbVie's skyrizi — net revenues changed year-over-year?
- AbbVie's skyrizi — net revenues increased by 32.5% year-over-year, from $3.78B to $5.01B.
- What is the long-term trend for AbbVie's skyrizi — net revenues?
- Over 4 years (2021 to 2025), AbbVie's skyrizi — net revenues has grown at a 56.3% compound annual growth rate (CAGR), from $2.94B to $17.56B.
- What does skyrizi — net revenues mean?
- The total net sales generated by the specific pharmaceutical product line during the reporting period.